You need to read the 10q and the trial again. IPIX has been working on oral K for a year. It was a parallel development. The 10q states only that they stopped recruiting and they will start a similar trial once oral K is ready.
I’m not the one twisting facts. I even posted the trial outcomes to back up what I said.
Finally, none of us know what Menon is up to or the full story of why his salary was cut. It could be anything from his becoming a consultant for a partner to he is preparing for retirement in the near future. The final 3 years of my university gig I enjoyed a phased retirement. My final year was 2 courses as a workload for all of 2017-2017, at half pay. You don’t know what the facts are.
Only here it's a negative when management takes a 50% pay cut and operating cost / dilution reduces as a result. Maybe Dr. Menon is working part-time now? Talk about twisting words.
Of course success isn't given in drug development. MOA was observed (primary endpoint met) in the first cohort so IPIX decided to save money and focus on oral formulation. Here's a proof of p53 modulation.
Yes you can ask questions. I've contacted Leo by phone and email before. You can also write your comments here.
Market Data 
Markets 
AI
